Floatz logo

Hycamtin

Extensive Stage Small Cell Lung Cancer

SUNHO（China）BioPharmaceutical CO., Ltd.Phase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

290 Active assets in the Extensive Stage Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →